Tag Archives: Lilly

ADA 2021: Novo trumpets higher-dose Ozempic data as Lilly competitors loom

Novo Nordisk’s semaglutide franchise has taken off in a big way. Type 2 diabetes med Ozempic smashed the blockbuster barrier in 2019, the same year the company launched its oral option, Rybelsus. Now, the Danish diabetes major is touting data on a higher-dose prospect. In a late-stage trial, Ozempic 2 mg trumped its 1-mg predecessor on blood… Read More »

EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod

BARCELONA—Eli Lilly and Boehringer Ingelheim, eager to keep pace with rivals, are out with new Jardiance kidney disease data in a patient population they say mirrors the one that could soon score Johnson & Johnson’s Invokana a new nod. Tuesday at the European Association for the Study of Diabetes annual meeting, the partners presented results showing… Read More »